<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="60354">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01855035</url>
  </required_header>
  <id_info>
    <org_study_id>Find-AF randomised</org_study_id>
    <nct_id>NCT01855035</nct_id>
  </id_info>
  <brief_title>Finding Atrial Fibrillation in Stroke - Evaluation of Enhanced and Prolonged Holter Monitoring</brief_title>
  <official_title>A Prospective, Randomised, Controlled Study to Determine the Detection of Atrial Fibrillation by Prolonged and Enhanced Holter Monitoring as Compared to Usual Care in Stroke Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut fuer anwendungsorientierte Forschung und klinische Studien GmbH</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut fuer anwendungsorientierte Forschung und klinische Studien GmbH</source>
  <oversight_info>
    <authority>Germany: Ethics Commission</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess whether repeated enhanced and prolonged ECG
      monitoring after ischemic stroke results in a higher detection of atrial fibrillation
      (/flutter) compared to usual care (at least 24 hour of cardiac monitoring).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Anticipated">November 2015</completion_date>
  <primary_completion_date type="Anticipated">May 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>number of atrial fibrillation/flutter</measure>
    <time_frame>30 month after study start</time_frame>
    <safety_issue>No</safety_issue>
    <description>The primary endpoint is the detection of newly diagnosed atrial fibrillation/flutter within 6 months and before occurrence of recurrent stroke or systemic embolism in the treatment group compared to control group.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>number of atrial fibrillation (/flutter) within 12 months after patient's inclusion</measure>
    <time_frame>24 months after study start</time_frame>
    <safety_issue>No</safety_issue>
    <description>Detection of newly diagnosed atrial fibrillation (/flutter) as defined for the primary endpoint but within 12 months after patient's inclusion. As patients are recruited for 12 months, this outcome measure is determined 24 months after study start.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of atrial fibrillation (/flutter) without hospitalisation</measure>
    <time_frame>30 months after study start</time_frame>
    <safety_issue>No</safety_issue>
    <description>Detection of newly diagnosed atrial fibrillation (/flutter) as defined for the primary endpoint with the exception that hospitalisation for atrial fibrillation (/flutter) will be considered as censoring.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of recurrent stroke or systemic embolism</measure>
    <time_frame>24 months after study start</time_frame>
    <safety_issue>No</safety_issue>
    <description>Recurrent stroke or systemic embolism within 12 months after patient's inclusion. As patients are recruited for 12 months, this outcome measure is determined 24 months after study start.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>total mortality</measure>
    <time_frame>24 months after study start</time_frame>
    <safety_issue>No</safety_issue>
    <description>Total death within 12 months after patient's inclusion. As patients are recruited for 12 months, this outcome measure is determined 24 months after study start.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of cardiovascular deaths</measure>
    <time_frame>24 months after study start</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of cerebrovascular deaths</measure>
    <time_frame>24 months after study start</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of transient ischemic attacks</measure>
    <time_frame>24 months after study start</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of myocardial infarctions</measure>
    <time_frame>24 months after study start</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of bleeding complications</measure>
    <time_frame>24 months after study start</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quality of life</measure>
    <time_frame>24 months after study start</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of atrial fibrillation (/flutter) in extended monitoring period</measure>
    <time_frame>24 months after study start</time_frame>
    <safety_issue>No</safety_issue>
    <description>Incremental detection of atrial fibrillation (/flutter) in the extended Holter monitoring periods after 3 and 6 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>costs</measure>
    <time_frame>24 months after study start</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of correct monitorings</measure>
    <time_frame>24 months after study start</time_frame>
    <safety_issue>No</safety_issue>
    <description>To assess the feasibility of monitoring procedures.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Stroke</condition>
  <arm_group>
    <arm_group_label>prolonged ECG monitoring</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Prolonged ECG monitoring: 10-day Holter ECG at months 0, 3 and 6</description>
  </arm_group>
  <arm_group>
    <arm_group_label>standard care</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Usual care according to current guidelines (minimum of 24 hours of cardiac monitoring).</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>prolonged ECG monitoring</intervention_name>
    <description>10-day Holter ECG measurement</description>
    <arm_group_label>prolonged ECG monitoring</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>standard care</intervention_name>
    <description>Usual care according to current guidelines (minimum of 24 hours of cardiac monitoring).</description>
    <arm_group_label>standard care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Recent cerebral ischemia defined as stroke (sudden focal neurologic deficit lasting &gt;
             24h consistent with the territory of a major cerebral artery and categorised as
             ischemic) and/or a corresponding lesion on brain imaging.

          -  Stroke symptoms started ≤ 7 days ago.

          -  Age ≥ 60 years.

          -  Modified Rankin scale ≤ 2 (prior to index event).

        Exclusion Criteria:

          -  Known history of atrial fibrillation/flutter or atrial fibrillation/flutter on
             admission ECG.

          -  Indication for oral anticoagulation at randomisation.

          -  Absolute contra-indication against oral anticoagulation at randomisation.

          -  Intracerebral bleeding in medical history.

          -  Patient scheduled for Holter-ECG or cardiac Event-Recording monitoring ≥ 48 hours.

          -  Significant carotid artery or vertebral artery stenosis &gt; 50% (NASCET
             classification), significant intracranial artery stenosis suspicious of
             atherosclerotic origin or acute arterial dissection explanatory of stroke symptoms.

          -  Implanted pacemaker device or cardioverter/defibrillator.

          -  Life expectancy &lt; 1 year for reasons other than stroke (e.g. metastatic cancer).

          -  Concomitant participation in other controlled randomised trial.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rolf Wachter, PD Dr. med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dept. of Cardiology and Pneumology, University Medical Center Goettingen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Klaus Gröschel, PD Dr.med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinic and Policlinic for Neurology, University of Mainz</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dept. of Cardiology and Pneumology, University Medical Center Goettingen</name>
      <address>
        <city>Goettingen</city>
        <zip>37075</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wachter, PD Dr. med.</last_name>
      <phone>+49-551-39-9258</phone>
      <email>wachter@med.uni-goettingen.de</email>
    </contact>
    <investigator>
      <last_name>Rolf Wachter, PD Dr. med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jan Liman, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Katrin Wasser, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Janin Wohlfahrt</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mark Weber-Krüger</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinic and Policlinic for Neurology, University of Mainz</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Klaus Gröschel, PD Dr. med.</last_name>
      <phone>+49-6131-173105</phone>
      <email>Klaus.groeschel@unimedizin-mainz.de</email>
    </contact>
    <investigator>
      <last_name>Klaus Gröschel, PD Dr. med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anne Grings</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dept. of Neurology, Nordwest-Hospital Sanderbusch</name>
      <address>
        <city>Sande</city>
        <zip>26452</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pawel Kermer, Prof. Dr. med.</last_name>
      <phone>+49-4422-801401</phone>
      <email>p.kermer@sanderbusch.de</email>
    </contact>
    <investigator>
      <last_name>Pawel Kermer, Prof. Dr. med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Evgeny Protsenko</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dept. of Neurology, HSK, Dr. Horst-Schmidt-Hospital</name>
      <address>
        <city>Wiesbaden</city>
        <zip>65199</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gerhard Hamann, Prof. Dr. med.</last_name>
      <phone>+49-611-43-2376</phone>
      <email>gerhard.hamann@hsk-wiesbaden.de</email>
    </contact>
    <investigator>
      <last_name>Gerhard Hamann, Prof. Dr. med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michaela Wagner-Heck, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jugoslav Erceg</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Joachim Hüwel, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sven Klimpe, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2013</verification_date>
  <lastchanged_date>October 28, 2013</lastchanged_date>
  <firstreceived_date>May 7, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ischemic stroke</keyword>
  <keyword>ECG monitoring</keyword>
  <keyword>atrial fibrillation (/flutter)</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Atrial Fibrillation</mesh_term>
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Cerebral Infarction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
